Department of Microbiology, University of Manitoba, R3T 2N2, Winnipeg, Manitoba, Canada,
Cytotechnology. 2006 Mar;50(1-3):57-76. doi: 10.1007/s10616-005-4537-x. Epub 2006 Jun 9.
Many biopharmaceuticals are now produced as secreted glycoproteins from mammalian cell culture. The glycosylation profile of these proteins is essential to ensure structural stability and biological and clinical activity. However, the ability to control the glycosylation is limited by our understanding of the parameters that affect the heterogeneity of added glycan structures. It is clear that the glycosylation process is affected by a number of factors including the 3-dimensional structure of the protein, the enzyme repertoire of the host cell, the transit time in the Golgi and the availability of intracellular sugar-nucleotide donors. From a process development perspective there are many culture parameters that can be controlled to enable a consistent glycosylation profile to emerge from each batch culture. A further, but more difficult goal is to control the culture conditions to enable the enrichment of specific glycoforms identified with desirable biological activities. The purpose of this paper is to discuss the cellular metabolism associated with protein glycosylation and review the attempts to manipulate, control or engineer this metabolism to allow the expression of human glycosylation profiles in producer lines such as genetically engineered Chinese hamster ovary (CHO) cells.
许多生物制药现在都是从哺乳动物细胞培养中作为分泌型糖蛋白生产的。这些蛋白质的糖基化谱对于确保结构稳定性和生物学及临床活性至关重要。然而,控制糖基化的能力受到我们对影响添加糖链结构异质性的参数的理解的限制。很明显,糖基化过程受到许多因素的影响,包括蛋白质的三维结构、宿主细胞的酶谱、高尔基体中的转运时间以及细胞内糖核苷酸供体的可用性。从工艺开发的角度来看,有许多可以控制的培养参数,可以使每个批次培养都具有一致的糖基化谱。更进一步但更困难的目标是控制培养条件,以使具有所需生物学活性的特定糖型得到富集。本文的目的是讨论与蛋白质糖基化相关的细胞代谢,并综述试图操纵、控制或设计这种代谢以允许在生产者系(如基因工程中国仓鼠卵巢(CHO)细胞)中表达人糖基化谱的尝试。